In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine

Sylvia B. Smith, Jennifer Duplantier, Ying Dun, Barbara Mysona, Penny Roon, Pamela M. Martin, Vadivel Ganapathy

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

PURPOSE. To evaluate the neuroprotective properties of the sigma receptor 1 (σR1) ligand, (+)-pentazocine in an in vivo model of retinal neurodegeneration. METHODS. Spontaneously diabetic Ins2Akita/+ and wild-type mice received intraperitoneal injections of (+)-pentazocine for 22 weeks beginning at diabetes onset. Retinal mRNA and protein were analyzed by RT-PCR and Western blot analysis. Retinal histologic sections were measured to determine total retinal thickness, thicknesses of inner- outer nuclear and plexiform layers (INL, ONL, IPL, INL), and the number of cell bodies in the ganglion cell layer (GCL). Immunolabeling experiments were performed using antibodies specific for 4-hydroxynonenal and nitrotyrosine, markers of lipid peroxidation, and reactive nitrogen species, respectively, and an antibody specific for vimentin to view radial Müller fibers. RESULTS. σR1 mRNA and protein levels in the Ins2Akita/+ retina were comparable to those in the wild-type, indicating that σR1 is an available target during the disease process. Histologic evaluation of eyes of Ins2Akita/+ mice showed disruption of retinal architecture. By 17 to 25 weeks after birth, Ins2Akita/+ mice demonstrated ∼30% and 25% decreases in IPL and INL thicknesses, respectively, and a 30% reduction in ganglion cells. In the (+)-pentazocine-treated group, retinas of Ins2Akita/+ mice showed remarkable preservation of retinal architecture; IPL and INL thicknesses of (+)-pentazocine-treated Ins2Akita/+ mouse retinas were within normal limits. The number of ganglion cells was 15.6 ± 1.5 versus 10.4 ± 1.2 cells/100 μm retinal length in (+)-pentazocine-treated versus nontreated mutant mice. Levels of nitrotyrosine and 4-hydroxynonenal increased in Ins2 Akita/+ retinas, but were reduced in (+)-pentazocine-treated mice. Retinas of Ins2Akita/+ mice showed loss of the uniform organization of radial Müller fibers. Retinas of (+)-pentazocine-treated mice maintained the radial organization of glial processes. CONCLUSION. Sustained (+)-pentazocine treatment in an in vivo model of retinal degeneration conferred significant neuroprotection, reduced evidence of oxidative stress, and preserved retinal architecture, suggesting that σR1 ligands are promising therapeutic agents for intervention in neurodegenerative diseases of the retina.

Original languageEnglish (US)
Pages (from-to)4154-4161
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume49
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Pentazocine
Ligands
Retina
Ganglia
sigma-1 receptor
Reactive Nitrogen Species
Retinal Degeneration
Messenger RNA
Antibodies
Vimentin
Intraperitoneal Injections
Neuroglia
Neurodegenerative Diseases
Lipid Peroxidation
Proteins
Oxidative Stress
Cell Count
Western Blotting
Parturition
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. / Smith, Sylvia B.; Duplantier, Jennifer; Dun, Ying; Mysona, Barbara; Roon, Penny; Martin, Pamela M.; Ganapathy, Vadivel.

In: Investigative Ophthalmology and Visual Science, Vol. 49, No. 9, 01.09.2008, p. 4154-4161.

Research output: Contribution to journalArticle

@article{429298fbe5464f6e86da39eb4211b0c3,
title = "In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine",
abstract = "PURPOSE. To evaluate the neuroprotective properties of the sigma receptor 1 (σR1) ligand, (+)-pentazocine in an in vivo model of retinal neurodegeneration. METHODS. Spontaneously diabetic Ins2Akita/+ and wild-type mice received intraperitoneal injections of (+)-pentazocine for 22 weeks beginning at diabetes onset. Retinal mRNA and protein were analyzed by RT-PCR and Western blot analysis. Retinal histologic sections were measured to determine total retinal thickness, thicknesses of inner- outer nuclear and plexiform layers (INL, ONL, IPL, INL), and the number of cell bodies in the ganglion cell layer (GCL). Immunolabeling experiments were performed using antibodies specific for 4-hydroxynonenal and nitrotyrosine, markers of lipid peroxidation, and reactive nitrogen species, respectively, and an antibody specific for vimentin to view radial M{\"u}ller fibers. RESULTS. σR1 mRNA and protein levels in the Ins2Akita/+ retina were comparable to those in the wild-type, indicating that σR1 is an available target during the disease process. Histologic evaluation of eyes of Ins2Akita/+ mice showed disruption of retinal architecture. By 17 to 25 weeks after birth, Ins2Akita/+ mice demonstrated ∼30{\%} and 25{\%} decreases in IPL and INL thicknesses, respectively, and a 30{\%} reduction in ganglion cells. In the (+)-pentazocine-treated group, retinas of Ins2Akita/+ mice showed remarkable preservation of retinal architecture; IPL and INL thicknesses of (+)-pentazocine-treated Ins2Akita/+ mouse retinas were within normal limits. The number of ganglion cells was 15.6 ± 1.5 versus 10.4 ± 1.2 cells/100 μm retinal length in (+)-pentazocine-treated versus nontreated mutant mice. Levels of nitrotyrosine and 4-hydroxynonenal increased in Ins2 Akita/+ retinas, but were reduced in (+)-pentazocine-treated mice. Retinas of Ins2Akita/+ mice showed loss of the uniform organization of radial M{\"u}ller fibers. Retinas of (+)-pentazocine-treated mice maintained the radial organization of glial processes. CONCLUSION. Sustained (+)-pentazocine treatment in an in vivo model of retinal degeneration conferred significant neuroprotection, reduced evidence of oxidative stress, and preserved retinal architecture, suggesting that σR1 ligands are promising therapeutic agents for intervention in neurodegenerative diseases of the retina.",
author = "Smith, {Sylvia B.} and Jennifer Duplantier and Ying Dun and Barbara Mysona and Penny Roon and Martin, {Pamela M.} and Vadivel Ganapathy",
year = "2008",
month = "9",
day = "1",
doi = "10.1167/iovs.08-1824",
language = "English (US)",
volume = "49",
pages = "4154--4161",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine

AU - Smith, Sylvia B.

AU - Duplantier, Jennifer

AU - Dun, Ying

AU - Mysona, Barbara

AU - Roon, Penny

AU - Martin, Pamela M.

AU - Ganapathy, Vadivel

PY - 2008/9/1

Y1 - 2008/9/1

N2 - PURPOSE. To evaluate the neuroprotective properties of the sigma receptor 1 (σR1) ligand, (+)-pentazocine in an in vivo model of retinal neurodegeneration. METHODS. Spontaneously diabetic Ins2Akita/+ and wild-type mice received intraperitoneal injections of (+)-pentazocine for 22 weeks beginning at diabetes onset. Retinal mRNA and protein were analyzed by RT-PCR and Western blot analysis. Retinal histologic sections were measured to determine total retinal thickness, thicknesses of inner- outer nuclear and plexiform layers (INL, ONL, IPL, INL), and the number of cell bodies in the ganglion cell layer (GCL). Immunolabeling experiments were performed using antibodies specific for 4-hydroxynonenal and nitrotyrosine, markers of lipid peroxidation, and reactive nitrogen species, respectively, and an antibody specific for vimentin to view radial Müller fibers. RESULTS. σR1 mRNA and protein levels in the Ins2Akita/+ retina were comparable to those in the wild-type, indicating that σR1 is an available target during the disease process. Histologic evaluation of eyes of Ins2Akita/+ mice showed disruption of retinal architecture. By 17 to 25 weeks after birth, Ins2Akita/+ mice demonstrated ∼30% and 25% decreases in IPL and INL thicknesses, respectively, and a 30% reduction in ganglion cells. In the (+)-pentazocine-treated group, retinas of Ins2Akita/+ mice showed remarkable preservation of retinal architecture; IPL and INL thicknesses of (+)-pentazocine-treated Ins2Akita/+ mouse retinas were within normal limits. The number of ganglion cells was 15.6 ± 1.5 versus 10.4 ± 1.2 cells/100 μm retinal length in (+)-pentazocine-treated versus nontreated mutant mice. Levels of nitrotyrosine and 4-hydroxynonenal increased in Ins2 Akita/+ retinas, but were reduced in (+)-pentazocine-treated mice. Retinas of Ins2Akita/+ mice showed loss of the uniform organization of radial Müller fibers. Retinas of (+)-pentazocine-treated mice maintained the radial organization of glial processes. CONCLUSION. Sustained (+)-pentazocine treatment in an in vivo model of retinal degeneration conferred significant neuroprotection, reduced evidence of oxidative stress, and preserved retinal architecture, suggesting that σR1 ligands are promising therapeutic agents for intervention in neurodegenerative diseases of the retina.

AB - PURPOSE. To evaluate the neuroprotective properties of the sigma receptor 1 (σR1) ligand, (+)-pentazocine in an in vivo model of retinal neurodegeneration. METHODS. Spontaneously diabetic Ins2Akita/+ and wild-type mice received intraperitoneal injections of (+)-pentazocine for 22 weeks beginning at diabetes onset. Retinal mRNA and protein were analyzed by RT-PCR and Western blot analysis. Retinal histologic sections were measured to determine total retinal thickness, thicknesses of inner- outer nuclear and plexiform layers (INL, ONL, IPL, INL), and the number of cell bodies in the ganglion cell layer (GCL). Immunolabeling experiments were performed using antibodies specific for 4-hydroxynonenal and nitrotyrosine, markers of lipid peroxidation, and reactive nitrogen species, respectively, and an antibody specific for vimentin to view radial Müller fibers. RESULTS. σR1 mRNA and protein levels in the Ins2Akita/+ retina were comparable to those in the wild-type, indicating that σR1 is an available target during the disease process. Histologic evaluation of eyes of Ins2Akita/+ mice showed disruption of retinal architecture. By 17 to 25 weeks after birth, Ins2Akita/+ mice demonstrated ∼30% and 25% decreases in IPL and INL thicknesses, respectively, and a 30% reduction in ganglion cells. In the (+)-pentazocine-treated group, retinas of Ins2Akita/+ mice showed remarkable preservation of retinal architecture; IPL and INL thicknesses of (+)-pentazocine-treated Ins2Akita/+ mouse retinas were within normal limits. The number of ganglion cells was 15.6 ± 1.5 versus 10.4 ± 1.2 cells/100 μm retinal length in (+)-pentazocine-treated versus nontreated mutant mice. Levels of nitrotyrosine and 4-hydroxynonenal increased in Ins2 Akita/+ retinas, but were reduced in (+)-pentazocine-treated mice. Retinas of Ins2Akita/+ mice showed loss of the uniform organization of radial Müller fibers. Retinas of (+)-pentazocine-treated mice maintained the radial organization of glial processes. CONCLUSION. Sustained (+)-pentazocine treatment in an in vivo model of retinal degeneration conferred significant neuroprotection, reduced evidence of oxidative stress, and preserved retinal architecture, suggesting that σR1 ligands are promising therapeutic agents for intervention in neurodegenerative diseases of the retina.

UR - http://www.scopus.com/inward/record.url?scp=53149105545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149105545&partnerID=8YFLogxK

U2 - 10.1167/iovs.08-1824

DO - 10.1167/iovs.08-1824

M3 - Article

C2 - 18469181

AN - SCOPUS:53149105545

VL - 49

SP - 4154

EP - 4161

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 9

ER -